Metraipolis › archive › dc_a324b6833f77

Enfortumab Vedotin in Advanced or Metastatic Urothelial Carcinoma: A Systematic Review of Efficacy, Safety, and Clinical Perspectives — Europe PMC PMID:42512387

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42512387
DOI
10.3390/cancers18142324
License (as archived)
solo-consultazione
Archived
2026-10-18T04:16:00.989Z
SHA-256 of the archived text
24bdb624a766e605d684552a54f899439ab201bf06ee9e4770ab0d4ff56c0aa4
Stable URL of this page
https://metraipolis.com/documento/dc_a324b6833f77

How to cite

Enfortumab Vedotin in Advanced or Metastatic Urothelial Carcinoma: A Systematic Review of Efficacy, Safety, and Clinical Perspectives — Europe PMC PMID:42512387 — Europe PMC (en), https://europepmc.org/article/MED/42512387 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a324b6833f77 (Metraipolis archive dc_a324b6833f77, sha256 24bdb624a766e605d684552a54f899439ab201bf06ee9e4770ab0d4ff56c0aa4)
BibTeX
@misc{dca324b6833f77,
  title = {Enfortumab Vedotin in Advanced or Metastatic Urothelial Carcinoma: A Systematic Review of Efficacy, Safety, and Clinical Perspectives — Europe PMC PMID:42512387},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42512387},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a324b6833f77; sha256 24bdb624a766e605d684552a54f899439ab201bf06ee9e4770ab0d4ff56c0aa4},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42512387. Agents can read the archived copy with the MCP tool read_document.